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he mammalian Golgi complex is comprised of a ribbon
of stacked cisternal membranes often located in the
pericentriolar region of the cell. Here, we report
that during apoptosis the Golgi ribbon is fragmented into
dispersed clusters of tubulo-vesicular membranes. We have
found that fragmentation is caspase dependent and identiﬁed
GRASP65 (Golgi reassembly and stacking protein of 65
kD) as a novel caspase substrate. GRASP65 is cleaved
T
 
speciﬁcally by caspase-3 at conserved sites in its membrane
distal COOH terminus at an early stage of the execution
phase. Expression of a caspase-resistant form of GRASP65
partially preserved cisternal stacking and inhibited break-
down of the Golgi ribbon in apoptotic cells. Our results
suggest that GRASP65 is an important structural component
required for maintenance of Golgi apparatus integrity.
 
Introduction
 
The mammalian Golgi complex is comprised of stacked cis-
ternal membranes that in animal cells are linked to form a
compact juxtanuclear ribbon (Rambourg and Clermont,
1997). The mechanism of Golgi stacking is poorly defined
but appears to involve proteins that form filamentous cross-
bridges between adjacent cisternae (Mollenhauer, 1965;
Franke et al., 1972; Cluett and Brown, 1992). Recent stud-
ies using an in vitro system for the postmitotic reassembly of
Golgi stacks from mitotic Golgi fragments (Rabouille et al.,
1995) have identified candidate stacking proteins.
The first stacking protein to be identified from in vitro
studies was GRASP65 (Golgi reassembly and stacking pro-
tein of 65 kD), an N-myristoylated peripheral membrane
protein localized predominantly to the cis side of the Golgi
complex (Barr et al., 1997). GRASP65 is a receptor for the
Golgi matrix protein GM130 (Barr et al., 1998) that in turn
binds the vesicle tethering protein p115 to mediate the dock-
ing of transport vesicles with Golgi membranes (Nakamura et
al., 1997; Sönnichsen et al., 1998). In addition to tethering
transport vesicles, GM130 and p115 are transiently required
during postmitotic stack formation, possibly for the initial
alignment of cisternae that occurs before the formation of
stable cross-bridges (Shorter and Warren, 1999). Impor-
tantly, GRASP65 has a function in stacking distinct from its
role as a GM130 receptor; it is required for stack formation
after the requirement for GM130 and p115 has passed,
although the details of this later activity are poorly defined
(Linstedt, 1999; Shorter and Warren, 1999). A second
stacking protein related to GRASP65 has been identified
recently. Although this protein, called GRASP55, is also
required for postmitotic stacking in vitro, its localization to
the medial-Golgi and lack of interaction with GM130 suggests
it is required at a step distinct from that mediated by
GRASP65 (Shorter et al., 1999).
The execution phase of apoptosis is characterized by sev-
eral dramatic morphological changes including cell shrink-
age, chromatin condensation, nuclear disassembly, and
membrane blebbing (Kerr et al., 1972; Wyllie et al., 1980).
Ultimately, these events lead to the fragmentation of the
cell, generating apoptotic bodies that are engulfed rapidly by
neighboring phagocytes. The execution phase requires the
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activation of a cascade of specific cysteine proteases termed
the caspases (for reviews see Cohen, 1997; Earnshaw et al.,
1999). These proteases are synthesized as inactive zymogens
that undergo cleavage during apoptosis, generating large and
small subunits that heterodimerize to yield the active en-
zyme. Caspases can be divided into two groups: the initiator
caspases, whose major function is to activate the second type
of caspases, and the executioner caspases, which are respon-
sible for the cleavage of specific target proteins. Cleavage is
highly selective and defined by an essential apartate residue
at the site of cleavage with differential recognition by partic-
ular family members dictated by residues immediately adja-
cent to the site of cleavage (Thornberry et al., 1997). Al-
though many caspase substrates have been identified, in only
Figure 1. Golgi fragmentation in apoptotic cells visualized by immunofluorescence microscopy. Immunofluorescence images of the Golgi 
complex in apoptotic HeLa cells. (a) Confocal images of HeLa cells treated for 6 h with 5  g/ml anisomycin, 1  g/ml anti-Fas antibody, or 
100 J/m
2 UV radiation and stained with antibodies to GM130 and cleaved PARP as indicated. DNA was stained with DAPI. The image on the 
right is a merge of GM130 (green), cleaved PARP (red), and DAPI (blue). (b) Confocal image of anisomycin-treated HeLa cells that had been 
preincubated with the cell permeable caspase inhibitor zVAD.fmk. Cells were stained with antibodies against GM130 (green), and the Golgi 
complex was imaged in rounded cells with partially condensed chromatin (DAPI, blue). Projected images of multiple confocal slices are 
shown. Bars, 10  m. 
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a few cases has the resulting cleavage been demonstrated to
have a role in apoptotic execution. For example, membrane
blebbing results from cleavage of Rho-associated kinase
ROCK1 (Coleman et al., 2001; Sebbagh et al., 2001),
whereas nuclear shrinkage and budding appears to require
cleavage of nuclear lamins (Rao et al., 1996).
Recent morphological studies have shown that the Golgi
complex is fragmented during apoptosis (Philpott et al., 1996;
Sesso et al., 1999; Mancini et al., 2000). The molecular mecha-
nisms underlying fragmentation are unknown. One molecule
that appears to be involved is golgin-160, a member of the gol-
gin family of coiled-coil proteins (Fritzler et al., 1993; Chan
and Fritzler, 1998). Golgin-160 is cleaved by caspases 2, 3, and
7, and a mutant from of golgin-160 lacking the caspase 2 cleav-
age site appears to delay Golgi fragmentation in apoptosis, sug-
gesting a role for this cleavage event in the morphological
changes observed (Mancini et al., 2000). However, since the
function of golgin-160 is unknown it is not clear how its cleav-
age contributes to the Golgi fragmentation process.
Here, we have studied the morphological changes that
occur during Golgi fragmentation in apoptosis at high
resolution and find that the Golgi ribbon is converted to tu-
bulo-vesicular membrane clusters morphologically similar to
those seen in mitosis. We identify GRASP65 as a substrate
for caspase-3 and find that it is quantitatively cleaved early
in the apoptotic execution phase. Furthermore, we show
that Golgi fragmentation in apoptotic cells is due, at least in
part, to GRASP65 cleavage, thereby providing the first di-
rect evidence that GRASP65 functions as a Golgi structural
protein in vivo.
 
Results
 
Morphological changes during apoptotic 
fragmentation of the Golgi complex
 
Previous studies that have addressed subcellular alterations
during apoptosis have reported fragmentation and/or scat-
tering of the Golgi complex (Philpott et al., 1996; Sesso et
al., 1999; Mancini et al., 2000). At present, this change in
organelle morphology remains ill defined, and the timing
and its significance during apoptosis is unknown. We have
used a combination of high resolution light microscopy and
EM to characterize this process in more detail. HeLa cells
were treated with several different stimuli to induce apopto-
sis and analyzed by immunofluorescence microscopy (Fig. 1
a). In healthy cells, the Golgi complex was a compact peri-
nuclear ribbon as expected (Fig. 1 a). In contrast, in apop-
totic cells, identified using an antibody specific for caspase-
cleaved PARP, the Golgi complex was fragmented into
punctate structures dispersed throughout the cytoplasm
(Fig. 1 a, left, arrowheads). The fragmentation observed was
independent of the apoptotic stimulus with morphologically
similar fragments produced in cells treated with the protein
synthesis inhibitor anisomycin, anti-Fas antibody, UV irra-
diation (Fig. 1 a), or the broad spectrum kinase inhibitor
staurosporine (see Figs. 4 and 8). The extent of fragmenta-
tion varied between different apoptotic cells in a population
(Fig. 1 a and Fig. 2; see Fig. 8), most likely reflecting the
length of time that a given cell had been in the apoptotic ex-
ecution phase. Similar changes to Golgi morphology were
observed in apoptotic HeLa, A431, and NRK cells (unpub-
lished data).
To determine if fragmentation requires caspase activity,
cells were pretreated with the cell-permeable caspase inhibitor
zVAD.fmk before apoptosis induction, and Golgi morphol-
ogy was analyzed. Even though caspases were not active un-
der these conditions (no cleaved PARP was detected; unpub-
lished data), cells committed to undergo apoptosis continued
to round-up as reported previously (McCarthy et al., 1997)
(Fig. 1 b, arrowhead). However, no Golgi fragmentation was
observed in these cells, demonstrating that gross changes in
Golgi organization are caspase dependent (Fig. 1 b).
Apoptotic fragmentation was observed using several dif-
ferent Golgi markers. Golgi fragments positive for the cis-
Golgi matrix protein GM130 were also positive for the
cis-Golgi–associated tethering protein p115 (Fig. 2, top).
GM130-containing fragments were also positive for the me-
dial-Golgi enzyme GalNacT2, although the extent of over-
lap was less than that observed in nonapoptotic cells (Fig. 2,
middle). In healthy cells, the trans-Golgi protein TGN46
colocalized with GM130, although a polarity could clearly
be distinguished in the Golgi ribbon (Fig. 2, bottom). In ap-
optotic cells, TGN46 was present in fragments dispersed
throughout the cytoplasm. In most cases, these appeared to
be distinct from GM130, although occasionally they ap-
peared to be adjacent to one another.
To study ultrastructural changes in Golgi morphology
during apoptosis, we performed EM. HeLa cells were treated
with staurosporine or anisomycin to induce apoptosis and
analyzed in Epon sections or frozen cryosections labeled
with antibodies to the medial-Golgi marker GalNacT2.
Analysis of Epon sections showed that there were essentially
no stacked cisternae remaining in the Golgi region of apop-
totic cells (Fig. 3 c). Instead, there were numerous small ve-
siculo-tubular structures of 
 
 
 
80 nm diameter together with
a few larger electron-lucent vesicles of 
 
 
 
100–200 nm diam-
eter (Fig. 3 c). Stereological analysis confirmed the absence
of stacked cisternae in apoptotic cells and revealed that
nearly 80% of the membrane in the Golgi region was in the
form of small vesicular structures with large vesicles account-
ing for the remaining 20% (Fig. 3 e). In cryosections,
GalNacT2 labeling was predominantly over stacked cister-
nae in nonapoptotic cells as expected (Fig. 3 a). Quantita-
tion revealed that 
 
 
 
60% of the GalNacT2 was in stacked
cisternae with the remaining 
 
 
 
40% in small vesicles (Fig. 3
f). In contrast, in apoptotic cells there was essentially no
GalNacT2 in stacks, and it was now found exclusively in
large and small vesicles that accounted for 
 
 
 
65 and 
 
 
 
35%
of the total labeling respectively (Fig. 3, b, d, and f). Inter-
estingly, although there was little change in the amount of
GalNacT2 in small vesicles between nonapoptotic and ap-
optotic cells, the loss of labeling in stacks could be fully ac-
counted for by the increase of label in large vesicles (Fig. 3 f).
This suggests that the large vesicles may be derived directly
from GalNacT2-containing cisternae. All of the morpholog-
ical changes observed were caspase dependent, since they
could be prevented by the cell-permeable caspase inhibitor
zVAD.fmk (unpublished data). Therefore, during apoptosis
Golgi stacks are converted into vesicular membrane clusters,
and this is dependent on caspase activation. 
498 The Journal of Cell Biology 
 
|
 
 
 
Volume 156, Number 3, 2002
 
GRASP65 is cleaved by caspase-3 during apoptosis
 
To address the mechanism of Golgi unstacking in apoptosis,
we analyzed whether known candidate stacking proteins are
subjected to caspase-mediated cleavage. Immunofluores-
cence analysis of NRK cells suggested that GRASP65 might
be cleaved during the apoptotic execution phase. Labeling of
NRK cells with a monoclonal antibody to GRASP65 re-
vealed that staining was lost in apoptotic cells (Fig. 4 a). To
confirm this was due to caspase-mediated cleavage, the fol-
lowing experiments were performed. First, purified rat liver
Golgi membranes were incubated with apoptotic cytosol,
and the status of GRASP65 was monitored by immunoblot-
ting. As shown in Fig. 4 b, reactivity to the GRASP65
monoclonal antibody was lost rapidly upon incubation with
apoptotic cytosol, and this was prevented by the caspase
inhibitor Ac-DEVD-CHO. Blotting with a polyclonal
GRASP65 antibody showed that the protein was quantita-
tively cleaved to an 
 
 
 
40-kD form that remained associated
with the membrane and that there are at least two cleavage
intermediates (Fig. 4 b). Cleavage was specific, since there
was little change in the total protein profile of the mem-
branes or the cytosol after incubation under apoptotic con-
ditions (Fig. 4 c).
To assess whether the other candidate Golgi stacking pro-
tein GRASP55 is also cleaved during apoptosis, samples
were subjected to immunoblotting with an antibody that
cross-reacts with both GRASP55 and GRASP65. Unlike
GRASP65, which was cleaved completely, there was no de-
tectable cleavage of GRASP55 even after a 6-h incubation in
apoptotic cytosol (Fig. 4 d). To confirm that GRASP65 is
cleaved by caspases in vivo, NRK cells were treated with
staurosporine for various lengths of time, and cell extracts
were analyzed by immunoblotting. GRASP65 was effi-
ciently cleaved to a 
 
 
 
40-kD form in apoptotic cells (Fig. 4
e). Cleavage of GRASP65 mirrored that of PARP with little
full-length protein remaining after a 4-h treatment with
staurosporine (Fig. 4 e). Cleavage of both GRASP65 and
PARP is inhibited by zVAD.fmk (Fig. 4 e).
Figure 2. Immunofluorescence microscopy of apoptotic cells labeled with different Golgi markers. Confocal images of anisomycin-treated 
HeLa cells stained with antibodies to GM130 and either p115, GalNacT2, or TGN46 as indicated. DNA was stained with DAPI. Regions of 
overlap between GM130 (red) and either p115, GalNacT2, or TGN46 (green) are in yellow. 2  magnifications of the boxed areas in the 
merged images are shown on the right. Apoptotic cells were identified by their rounded morphology and characteristic condensed chromatin 
and are indicated by arrowheads. Projected images of multiple confocal slices are shown. Bars,10  m (2  m for zooms). 
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Recent studies have localized caspase-2 to the Golgi com-
plex (Mancini et al., 2000). To determine whether caspase-2
was responsible for the cleavage of GRASP65, we first per-
formed incubations in the presence of Casputin™, a novel
caspase inhibitor that specifically inhibits caspases 3 and 7
but has no effect on other known caspases including caspase-2.
Cytosol was preincubated with cytochrome c for 90 min
to induce caspase activation; immunoblotting with antibod-
ies to caspases 2 and 3 confirmed that these had been cleaved
from their inactive p48 and p32 proforms to the active p12
and p17 forms, respectively (Fig. 5 a, left). Preactivated ap-
optotic cytosol efficiently cleaved GRASP65, but when Cas-
putin™ was present cleavage was abolished completely (Fig.
5 a, right), suggesting that GRASP65 is cleaved by caspase-3
Figure 3. Ultrastructural changes in 
Golgi morphology during apoptosis. 
(a–d) HeLa cells were incubated with 
DMSO (a, control), 1  M staurosporine 
(b), or 5  g/ml anisomycin (c and d) for 
6 h before fixation and preparation for 
Epon embedding (c) or cryo-EM and 
labeling with antibodies to GalNacT2 
followed by secondary antibodies 
conjugated to 10 nm gold (a, b, and d). 
Arrowheads in c indicate a vesicular 
membrane cluster. Gold particles in a, b, 
and d are indicated by small arrows. (e) 
Quantitation of membrane profiles in 
the Golgi region of Epon sections of cells 
incubated under control conditions (non-
apoptotic) or with 5  g/ml anisomycin 
(apoptotic). Quantitation was performed 
as described in Materials and methods. 
Bars represent the mean   SEM (n   
20–24). (f) Quantitation of GalNac T2 
labeling of cryosections. The relative 
number of gold particles over stacked 
cisternae compared with small and large 
vesicular profiles was counted for cells 
incubated under control conditions (non-
apoptotic) or with 5  g/ml anisomycin 
(apoptotic). Bars represent the mean   
SEM (n   18–29). Bar, 200 nm. 
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Figure 4.
 
GRASP65 is a substrate for caspase-mediated proteolysis during apoptosis. 
 
(a) NRK cells treated with 1 
 
 
 
M staurosporine for 4 h 
were processed for immunofluorescence microscopy. (Top) Cells were double labeled with polyclonal antibodies to GM130 and a monoclonal 
antibody to GRASP65. Regions of overlap between GM130 (red) and GRASP65 (green) are shown in the merge in yellow. Apoptotic cells 
were identified using DAPI (unpublished data) and are indicated by arrowheads. (Bottom) Cells were labeled with polyclonal antibodies to 
cleaved PARP, a monoclonal antibody to GRASP65, and DAPI as indicated. A merged image showing cleaved PARP (red), GRASP65 (green), 
and DAPI (blue) is on the right. (b) Purified Golgi membranes were incubated at 37
 
 
 
C with apoptotic HeLa cytosol in the absence or presence  
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or caspase-7. Cleavage of golgin-160 was unaffected by Cas-
putin™ consistent with the observation that golgin-160 is a
substrate for caspase-2 (Mancini et al., 2000).
To determine whether GRASP65 is directly cleaved by
caspase-3 or caspase-7, in vitro–translated GRASP65 was in-
cubated with increasing concentrations of purified recombi-
nant caspases and cleavage analyzed by SDS-PAGE. As
shown in Fig. 5 b, GRASP65 was quantitatively cleaved to
an 
 
 
 
40-kD form by caspase-3 but was not affected by cas-
pase-7 even though similar amounts of activity were present
in each incubation. As expected, GRASP65 was also not af-
fected by caspase-2 even though this enzyme could effi-
ciently cleave golgin-160 and a control substrate (Fig. 5 b).
To further confirm GRASP65 is a substrate for caspase-3
only, in vitro–translated GRASP65 was incubated with cy-
tosol prepared from caspase-3–deficient MCF-7 cells. No
cleavage of GRASP65 was observed with apoptotic MCF-7
cytosol, whereas the control protein PARP, a substrate for
caspase-7 and caspase-3, was completely processed under the
same conditions (Fig. 5 c). Incubation with apoptotic cyto-
sol prepared from MCF-7 cells stably expressing GFP-
tagged caspase-3 restored GRASP65 cleavage (Fig. 5 c).
Cleavage of GRASP65 was not complete, most likely due to
the low amount of caspase-3 activation observed with this
cytosol (Fig. 5 c, left). Together, our results strongly suggest
GRASP65 is a specific substrate for caspase-3.
 
of 2 
 
 
 
M Ac-DEVD-CHO (D) for the times indicated. Membranes were pelleted, and membrane and supernatant (cytosol) fractions were 
analyzed by immunoblotting with monoclonal or polyclonal (FBA31) antibodies to GRASP65 or antibodies to mannosidase I. (c and d) Golgi 
membranes were incubated with HeLa control cytosol or apoptotic cytosol in the absence or presence of 2 
 
 
 
M Ac-DEVD-CHO for 4 h at 
37
 
 
 
C. Membrane and cytosol fractions were analyzed by Coomassie blue staining (c) or immunoblotting with an antipeptide antibody that 
recognizes both GRASP55 and GRASP65 (d). (e) NRK cells treated with 1 
 
 
 
M staurosporine in the absence or presence of 50 
 
 
 
M zVAD.fmk 
(Z) for the times indicated were analyzed by immunoblotting with monoclonal and polyclonal (CT) antibodies to PARP and GRASP65, 
respectively. (b, d, and e) Full-length (FL) and caspase cleavage products (asterisks) are marked. Bars, 10 
 
 
 
m.
Figure 5. GRASP65 is cleaved by caspase-3. (a) HeLa cytosols preincubated in the absence (control) or presence (apoptotic) of 10  M 
cytochrome c for 90 min at 37 C were immunoblotted with antibodies to caspase-3 and caspase-2 (left). Golgi membranes were incubated 
with control or apoptotic cytosol in the absence or presence of 80  g/ml Casputin™ for 4 h at 37 C and analyzed by immunoblotting with 
polyclonal antibodies to GRASP65 and golgin-160 (right). (b) In vitro–translated 
35S-labeled control proteins, GRASP65, or golgin-160 were 
incubated with purified recombinant caspases at the indicated concentrations for 2 h at 30 C before SDS-PAGE and autoradiography. Control 
proteins were PARP (for caspases 3 and 7 at 0, 0.025, 0.1, 0.25, 0.5, 1, 2, and 4 nM) and procaspase 2 (for caspase 2 at 0, 0.5, 1, 2.5, 10, 25, 
100, and 250 nM). (c) In vitro–translated 
35S-labeled PARP or GRASP65 were incubated with control (C) or apoptotic (A) cytosol from the 
parental MCF-7 cell line (WT) or MCF-7 cells stably expressing GFP–caspase-3 (C3-GFP) for 2 h at 30 C. Samples were analyzed by SDS-PAGE 
followed by immunoblotting with antibodies to GFP or autoradiography. Full-length (FL) and caspase cleavage products (asterisks) are 
indicated. The additional 27-kD band ( ) in the left panel likely corresponds to free GFP. 
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Identification of the cleavage site
 
Analysis of the GRASP65 sequence revealed the absence of a
protypical DEXD caspase-3 cleavage site. Since our bio-
chemical results suggested GRASP65 cleavage was occurring
in the COOH-terminal half of the protein, we analyzed the
sequence in this region and identified three potential cleav-
age sites as SLLD
 
320
 
S, SFPD
 
375
 
S, and TLPD
 
393
 
G (Fig. 6 a).
The relevant aspartic acid residues at each of these sites were
mutated to alanine either alone or in combination, and
cleavage of the resulting constructs by apoptotic cytosol was
analyzed. Although mutation of each site alone or in combi-
nation with one other site resulted in cleavage at the remain-
ing nonmutated site(s), mutation of all three aspartic acid
residues completely blocked cleavage (Fig. 6 b).
To demonstrate that the same sites are also used in vivo, wild-
type and triple mutant GRASP65 were tagged at the COOH
terminus with GFP, and stable cell lines expressing each con-
struct were generated. Immunofluorescence microscopy and
 
immunoblotting analysis confirmed that both proteins are tar-
geted correctly to the Golgi apparatus in these cells and that
they are expressed at similar levels, likely corresponding to a 5-
to 10-fold overexpression relative to endogenous GRASP65
(Figs. S1 and S2). Wild-type and mutant cells were incubated
with staurosporine for various lengths of time and then ana-
lyzed by immunoblotting with antibodies to GFP and PARP.
As shown in Fig. 6 c, wild-type GRASP65-GFP was efficiently
cleaved, generating GFP antibody-reactive cleavage products at
 
 
 
30–35 kD. In contrast, triple mutant GRASP65-GFP was
completely resistant to cleavage even after a 20-h incubation in
staurosporine, during which time PARP was processed com-
pletely (Fig. 6 c). Therefore, SLLD, SFPD, and TLPD are the
only GRASP65 caspase cleavage sites both in vitro and in vivo.
 
GRASP65 cleavage visualized in living cells
 
To study the dynamics of GRASP65 cleavage during apop-
tosis, GRASP65-GFP–expressing cells were treated with ani-
Figure 6. Identification of the GRASP65 cleavage sites. (a) Schematic representation of the structure of GRASP65. (b) In vitro–translated 
35S-labeled GRASP65 proteins with the indicated aspartic acid to alanine substitutions were incubated with control or apoptotic HeLa cytosol 
in the absence or presence of 2  M Ac-DEVD-CHO for 4 h at 37 C and analyzed by SDS-PAGE and autoradiography. (c) HeLa cells stably 
expressing COOH terminally GFP-tagged wild-type and D320A/D375A/D393A triple mutant forms of GRASP65 were incubated with 1  M 
staurosporine for the times indicated. Cell extracts were analyzed by immunoblotting with antibodies to GFP and PARP. 
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somycin and observed by time-lapse fluorescence and phase–
contrast microscopy. Alexa 594–conjugated annexin V was
included in the medium to determine the onset of phos-
phatidylserine exposure, a hallmark of apoptotic progression
(Martin et al., 1995). GFP fluorescence dissipated rapidly
from the Golgi apparatus at the same time as the cells started
to round up and exhibit plasma membrane blebbing (Fig. 7
a; Video 1 available at http://www.jcb.org/cgi/content/full/
jcb.200110007/DC1). This was not due to Golgi mem-
branes moving out of focus because similar analysis of cells
expressing a GFP-tagged Golgi luminal protein (NAGT1)
undergoing apoptosis showed that GFP fluorescence was
visible on clearly discernible structures for the duration of
the experiment (unpublished data). Furthermore, confocal
optical sectioning of live apoptotic GRASP65-GFP cells
showed that GFP was not present on any structure through-
out the whole thickness of the cell (Fig. 7 c, top). Loss of
GFP fluorescence from the Golgi region occurred as soon as
cell rounding could be observed. The average time from cell
rounding to complete loss of Golgi-associated GFP fluores-
cence was only 9.8 min (SD 
 
 
 
 3.9, 
 
n
 
 
 
 
 
 14), significantly
faster than the time from cell rounding to phosphati-
dylserine exposure, which took 89.7 min (SD 
 
 
 
 16.8, 
 
n 
 
 
 
10). These results demonstrate that complete cleavage of
GRASP65 is a rapid event that occurs very early in the exe-
cution phase of apoptosis.
Figure 7. Real-time visualization of GRASP65 cleavage. Still images taken from time-lapse analyses of Golgi morphology in HeLa cells 
stably expressing wild-type GRASP65-GFP (a) or caspase-resistant mutant GRASP65-GFP (b). Cells were treated with anisomycin in the presence 
of Alexa 594–conjugated annexin V (red). The onset of apoptotic execution is marked by an arrow in the fluorescence panels. GFP fluorescence 
associated with Golgi fragments in apoptotic cells in b is indicated by arrowheads. Time elapsed from the beginning of each sequence is 
shown in minutes. Videos 1 and 2 are available online at http://www.jcb.org/cgi/content/full/jcb.200110007/DC1. (c) Confocal images of 
living anisomycin-treated wild-type and caspase-resistant GRASP65-GFP stable HeLa cells. Cells were incubated with annexin V conjugated 
to Alexa 594 to identify apoptotic cells. Projections of multiple confocal sections are shown. Bars, 10  m. 
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Does GRASP65 cleavage occur before Golgi fragmenta-
tion? Time-lapse analysis of cells expressing GFP-tagged
NAGT1 demonstrated that the Golgi ribbon starts to frag-
ment 
 
 
 
30 min after cell rounding (unpublished data), sug-
gesting this occurs 
 
 
 
20–30 min after GRASP65 cleavage.
However, due to our inability to visualize GRASP65 cleav-
age and Golgi fragmentation in the same cells by time-lapse
microscopy we decided to use the monoclonal anti-
GRASP65 antibody to label fixed cells and monitor
GRASP65 cleavage in combination with changes to Golgi
Figure 8. GRASP65 cleavage is required for fragmentation of the Golgi ribbon during apoptosis. The progress of Golgi fragmentation was 
analyzed in standard HeLa cells and cells stably expressing wild-type GRASP65-GFP or caspase-resistant mutant GRASP65-GFP. Staurosporine-
treated cells (6 h) were fixed and then stained with a monoclonal antibody against GM130 (detected with Alexa 488–conjugated secondary 
antibody) and caspase-cleaved PARP (detected with Alexa 594 secondary antibody). (a) Cells were categorized for apoptotic progression (stage 
1, PARP-positive nucleus with normal uncondensed chromatin; stage 2, PARP-positive nucleus with condensed chromatin; stage 3, highly 
condensed chromatin and PARP staining throughout the cell). (b) The condition of the Golgi apparatus was then assessed in apoptotic cells 
according to the parameters shown. (c) The proportion of cells displaying each category of Golgi morphology was quantitated in each of the 
three stages of apoptosis. All counting was performed blind. Means   SEM are shown for three independent experiments. The total number of 
cells counted for each cell type was between 108–144 (stage 1), 358–392 (stage 2), and 35–72 (stage 3). Using the chi-square likelihood ratio 
contingency test, there was no significant difference at any stage between cells stably expressing wild-type GRASP65-GFP and the parental cells. 
For all experiments, there was a significant difference in the percentage of cells with stage 3 fragmented Golgi between cells expressing mutant 
GRASP65-GFP and either the parental cells (P   0.001) or the wild-type GRASP65-GFP–expressing cells (P   0.02). For stage 2, there was a 
significant difference in two out of three experiments between the mutant GRASP65-GFP cells and the parental cells and in all experiments 
between the mutant and wild-type GRASP65-GFP cells (P   0.0167), whereas for stage 1 this was true in one out of three experiments. 
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structure. Quantitation of staurosporine-treated NRK cells
revealed that 91% of cells that had cleaved GRASP65 had a
fragmented Golgi (
 
n
 
 
 
 
 
 144) and that there were never any
cells with a fragmented Golgi that had intact GRASP65
(
 
n
 
 
 
  
 
200). This indicates that cleavage of GRASP65 occurs
before Golgi fragmentation.
Time-lapse analysis of cells expressing caspase-resistant
GRASP65-GFP was also performed. In this case, GFP fluo-
rescence remained associated with Golgi membranes up
to and beyond the onset of annexin V labeling (Fig. 7 b;
Video 2 available at http://www.jcb.org/cgi/content/full/
jcb.200110007/DC1). Confocal analysis of live cells con-
firmed the presence of GRASP-GFP on Golgi membranes in
annexin V–positive cells (Fig. 7 c, bottom).
 
Cleavage of GRASP65 is required for Golgi 
fragmentation during apoptosis
 
Previous work has shown that GRASP65 is required for the in
vitro reformation of Golgi stacks from mitotic Golgi fragments
during postmitotic reassembly of the Golgi complex (Barr et
al., 1997; Shorter and Warren, 1999). In vivo evidence sup-
porting a role for GRASP65 in stacking is lacking currently. It
is also not clear whether GRASP65 is involved in generating
the higher order ribbon structure of the Golgi complex. We
decided to investigate whether GRASP65 cleavage is required
for loss of stacking and/or breakdown of the Golgi ribbon dur-
ing apoptosis by studying fragmentation in cells expressing the
noncleavable form of this protein. Should GRASP65 have a
role in maintaining these structures, then expression of the cas-
pase-resistant form might be expected to slow down the mor-
phological changes that occur during apoptosis.
Initial experiments addressed whether GRASP65 cleavage
is involved in breakdown of the Golgi ribbon. GRASP65-
GFP–expressing cells were treated with staurosporine for 6 h
and then fixed and stained with antibodies to GM130 and
cleaved PARP to determine the extent of Golgi fragmenta-
tion and the stage of apoptosis, respectively. Three stages of
apoptosis were scored: stage 1 cells had nuclei that were pos-
itive for cleaved PARP but contained normal looking un-
condensed chromatin, indistinguishable from healthy cells;
stage 2 cells had nuclei positive for cleaved PARP and con-
tained condensed marginalized chromatin; and stage 3 cells
had highly condensed and fragmented chromatin in combi-
nation with cleaved PARP staining distributed throughout
the cytoplasm (Fig. 8 a). Golgi morphology was assessed in
these cells and split into three categories. These are “wild-
type ribbons” (a continuous juxtanuclear ribbon of normal
appearance), “mixed ribbons and scattered Golgi fragments”
(clearly discernible ribbons with a few dispersed punctate
fragments of smaller size), or “scattered Golgi fragments”
(no ribbon-like structure remaining and many punctate
fragments dispersed throughout the cell) (Fig. 8 b). Expres-
sion of wild-type GRASP65-GFP had no effect on the
progress of apoptotic Golgi fragmentation (Fig. 8 c). In con-
trast, the transition from mixed ribbons and scattered Golgi
fragments into scattered Golgi fragments only, indicating
complete breakdown of the Golgi ribbon, was reduced sig-
nificantly in cells expressing caspase-resistant GRASP65
compared with the parental cells and cells expressing wild-
type GRASP65 (Fig. 8 c). This was true for cells at both
stages 2 and 3. Expression of the caspase-resistant GRASP65
mutant therefore significantly inhibited breakdown of the
Golgi ribbon.
To assess whether GRASP65 cleavage is required for the
loss of Golgi stacking observed during apoptosis, the
GRASP65-GFP cells were treated with anisomycin and ana-
lyzed by EM. Apoptotic cells were identified by their con-
densed chromatin, and the amount of membrane in cisternal
stacks and large and small vesicles was quantitated by stere-
ology. Wild-type GRASP65 had no effect on the loss of
Golgi stacking or on the accumulation of large and small
vesicles during apoptosis (Fig. 9 compared with Fig. 3 e). In
cells expressing caspase-resistant GRASP65, the majority of
membrane in the Golgi region was also converted into large
and small vesicles during apoptosis (Fig. 9). However, there
was a small but significant increase in the amount of mem-
brane remaining in stacked cisternae, and this was mirrored
by a decrease in the amount of membrane in small vesicles
(Fig. 9). In nonapoptotic cells, 57% of the total membrane
in the Golgi region was in stacked cisternae (Fig. 3 e). In
GRASP65 mutant cells, this number was 13% compared
with only 1% in cells expressing wild-type GRASP65 (Fig.
9). Therefore, 
 
 
 
23% (13/57) of membrane stacking was
preserved in GRASP65 mutant cells compared with only
1.7% (1/57) in wild-type cells.
 
Discussion
 
In this paper, we have shown that the Golgi complex is frag-
mented into clusters of tubulo-vesicular membranes during
apoptosis. Fragmentation was caspase dependent, suggesting
that caspase-mediated cleavage of target proteins is required
to bring about the morphological changes observed. We
identified one of the caspase targets as GRASP65, a protein
identified originally as a stacking factor using a cell-free assay
for the postmitotic assembly of Golgi stacks from mitotic
Golgi fragments (Barr et al., 1997). Although GRASP65 is
clearly required for stacking in this assay, the mechanism by
Figure 9. Ultrastructural analysis of Golgi fragmentation in cells 
expressing caspase-resistant GRASP65. HeLa cells stably expressing 
wild-type (WT) or caspase-resistant GRASP65-GFP (mutant) were 
treated with 5  g/ml anisomycin for 6 h, fixed, and embedded in 
Epon for analysis by EM. Membrane profiles were quantitated as 
described in Materials and methods. Bars represent the mean   
SEM (n   20–24). 
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which stacking is promoted is not clear. It has been postu-
lated that GRASP65 acts to promote the formation of stable
cross-bridges between newly forming cisternae that have pre-
viously become tethered in a p115-dependent manner (Lin-
stedt, 1999; Shorter et al., 1999). Whether GRASP65 is re-
quired only transiently during cross-bridge formation or has
a more permanent role in maintaining stable cross-bridges
once they have formed is not clear.
We found that expression of caspase-resistant GRASP65
retained a small amount of cisternal stacking in apoptotic
cells, suggesting GRASP65 plays some role in maintenance
of preformed stacks. The amount of cisternal stacking re-
tained corresponded to only 
 
 
 
23% of that found in a non-
apoptotic cell. However, since GRASP65 is restricted to the
cis-most cisterna of the Golgi stack (Shorter et al., 1999), it
would only be expected to link this cisterna with its adjacent
partner. The Golgi complex of our HeLa cells has on average
three stacked cisternae, so even if stacking between the two
cis-most cisternae was fully protected this would correspond
to only 
 
 
 
50% of the total stacking of a nonapoptotic cell.
Therefore, caspase-resistant GRASP65 may protect 
 
 
 
50%
(23/50) of stacking at the cis side of the Golgi stack. The re-
mainder of stacking was lost in cells expressing caspase-resis-
tant GRASP65 consistent with a lack of GRASP65 involve-
ment in stacking other Golgi cisternae. Therefore, other
proteins must be responsible for stacking these cisternae, and
these proteins are likely targets for apoptotic cleavage. One
candidate is GRASP55, but we found that GRASP55 is re-
sistant to caspase-mediated cleavage, suggesting additional
proteins are involved.
Expression of the caspase-resistant mutant significantly in-
hibited breakdown of the Golgi ribbon in apoptotic cells.
This suggests that GRASP65 cleavage is required for frag-
mentation of the Golgi ribbon during apoptosis. Impor-
tantly, it also suggests that GRASP65 plays an important
role in generating the higher order ribbon structure of the
Golgi apparatus. Recent work has shown that matrix pro-
teins including GRASP65 can generate a Golgi ribbon that
lacks Golgi resident enzymes (Seemann et al., 2000). This
suggests that matrix proteins are sufficient for ribbon forma-
tion and is consistent with the idea that GRASP65 functions
in this process. How GRASP65 might participate in ribbon
formation and how this relates to a role in cisternal stacking
is not clear. GRASP65 binds to the Golgi matrix protein
GM130 via its NH
 
2
 
 terminus, and GM130 in turn binds
p115 (Nakamura et al., 1997; Barr et al., 1998). However,
the NH
 
2
 
 terminus of GRASP65 is not affected during apop-
tosis, and GM130 and p115 remain associated with apop-
totic Golgi membranes, suggesting these proteins are not in-
volved in the morphological changes observed. Cleavage of
GRASP65 occurs in the membrane-distal COOH terminus,
suggesting this part of the protein is important for mainte-
nance of Golgi structure. The COOH terminus may be re-
quired for oligomerization of GRASP65 or for binding other
stacking and/or matrix proteins. Identification of other pro-
teins that bind GRASP65 should help unravel the roles of
this protein in stacking and ribbon formation and reveal
how these apparently separate processes might be linked.
Golgi fragments produced during apoptosis are morpho-
logically similar to the Golgi clusters found in mitotic cells
 
(Warren et al., 1995). Mitotic fragmentation is depen-
dent on phosphorylation of Golgi proteins by mitotically ac-
tive protein kinases including cyclin-dependent kinase
(CDK)*1, polo-like kinase-1, and a mitotic form of mito-
gen-activated protein kinase kinase 1 (Lowe et al., 1998;
Colanzi et al., 2000; Sutterlin et al., 2001). It has been re-
ported that CDK1 activation can occur in apoptotic cells
(Zhou et al., 1998), raising the possibility that the morpho-
logical changes we observe are a consequence of mitotic
phosphorylation rather than caspase-mediated cleavage of
Golgi targets. However, we think this unlikely, since we
could detect no significant increase in the histone kinase ac-
tivity of apoptotic cell extracts nor could we detect any in-
crease in phosphorylation of the CDK1 substrate GM130
(unpublished data). Furthermore, in agreement with previ-
ous studies (Zhou et al., 1998) we found no increase in reac-
tivity of apoptotic cells to the mitotic phosphoepitope-spe-
cific antibody MPM2 (unpublished data). We also found
no significant increase in mitogen-activated protein kinase
phosphorylation in apoptotic cells (unpublished data).
Therefore, we believe the morphological changes we observe
are a direct consequence of caspase-mediated cleavage of
Golgi proteins.
Are similar pathways used for fragmentation during apop-
tosis and mitosis with common proteins targeted by the mi-
totic (kinases) and apoptotic (caspases) machinery? Interest-
ingly, GRASP65 is highly phosphorylated in mitosis (Barr et
al., 1997), and this is likely important for regulation of its
function. Mitotic phosphorylation is mediated by polo-like
kinase-1 and CDK1 and occurs in the COOH-terminal re-
gion of the protein (Lin et al., 2000; Sutterlin et al., 2001).
Therefore, GRASP65 is targeted during apoptosis and mito-
sis. This not only supports the idea that GRASP65 is a key
structural protein of the Golgi complex but also suggests
that common fragmentation pathways may be used in each
situation. To determine if this is the case will require further
work. However, we already know of one difference: the vesi-
cle tethering protein p115 is removed rapidly from Golgi
membranes during mitosis (Lowe et al., 2000) but remains
membrane bound throughout the execution phase of apop-
tosis consistent with a lack of GM130 phosphorylation in
apoptotic cells.
Why fragment the Golgi complex during apoptosis? Pres-
ently, we can only speculate, but one reason may be to allow
inclusion of the normally single copy Golgi ribbon into ap-
optotic bodies destined for clearance by phagocytosis. Frag-
mentation might also play a role in maintaining peripheral
tolerance in the immune system by allowing Golgi compo-
nents to be phagocytosed by antigen-presenting dendritic
cells (Steinman et al., 2000). Interestingly, cytoplasmic dy-
nein function is lost in apoptotic cells due to caspase-medi-
ated cleavage of the dynein intermediate chain and p150
 
glued
 
(Lane et al., 2001). Since cytoplasmic dynein is required
for maintenance of a perinuclear ribbon in healthy cells
(Burkhardt et al., 1997), loss of function may account for
the dispersal of Golgi fragments seen in apoptotic cells and
may facilitate the inclusion of these fragments into apoptotic
bodies.
 
*Abbreviation used in this paper: CDK, cyclin-dependent kinase. 
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It is likely that other Golgi proteins are cleaved by caspases
during apoptosis. The identification of these proteins will
not only lead to a greater understanding of how the Golgi
complex undergoes fragmentation during apoptosis but
should also lead to a more general understanding of how
Golgi complex structure is controlled at the molecular level.
Our aim now is to identify these proteins.
 
Materials and methods
 
Antibodies
 
The following antibodies were used: FBA31 and CT polyclonal anti-
GRASP65, FBA19 polyclonal anti-GRASP55 and GRASP65, 7E10 monoclonal
anti-GRASP65, MLO7 polyclonal anti-GM130, 4H1 monoclonal anti-p115,
3E1 monoclonal anti-GFP, monoclonal anti-GM130 from Transduction Labs,
polyclonal anti-PARP p85 fragment from Promega (human specific) and Cell
Signaling (rat specific), monoclonal anti-Fas (DX2) from Calbiochem, mono-
clonal anti-GalNac T2 (a gift from Dr. Henrik Clausen, University of Copen-
hagen, Copenhagen, Denmark), polyclonal anti-TGN46 (a gift from Dr. Vas
Ponnambalam, Leeds University, Leeds, UK), monoclonal anti-PARP from
Calbiochem and polyclonal anti–caspase 2 (C-20) and –caspase 3 (N-19) from
Santa Cruz Biotechnology, Inc., polyclonal anti–golgin-160 (a gift from Dr. Ed
Chan, The Scripps Research Institute, La Jolla, CA). Fluorophore-conjugated
secondary antibodies were purchased from Molecular Probes. HRP-conju-
gated secondary antibodies were purchased from Tago Immunologicals.
 
Constructs
 
Amino acid substitutions were introduced into full-length rat GRASP65
cDNA using the QuickChange kit (Stratagene) according to the manufac-
turer’s instructions. To generate GRASP65-GFP, full-length GRASP65 was
amplified by PCR and cloned in-frame into the XmaI site of pEGFP-N2
mammalian expression vector (CLONTECH Laboratories, Inc.). All con-
structs were verified by DNA sequencing.
 
Cell culture and drug treatments
 
HeLa and NRK cells were grown in DME containing 10% FCS. To induce
apoptosis, cells were treated with 1 
 
 
 
g/ml anti-Fas monoclonal antibody
DX2 (Calbiochem) plus 0.1 mg/ml cycloheximide, 100 J/m
 
2
 
 UV radiation,
1–2 
 
 
 
M staurosporine (Sigma-Aldrich), or 5 
 
 
 
g/ml anisomycin (Calbio-
chem). In some cases, cells were pretreated for 15 min with 50 
 
 
 
M
zVAD.fmk (Calbiochem) before apoptotic stimulus.
 
Generation of GRASP65-GFP stable cell lines
 
HeLa cells were transfected with wild-type or caspase-resistant GRASP65-
GFP plasmids using Fugene 6 (Roche Biochemicals) according to the man-
ufacturer’s instructions. Transfected cells were grown in the presence of
geneticin (G418) until individual clones could be distinguished. Clonal
colonies were screened for Golgi-associated GFP fluorescence, and those
clones expressing correctly localized GRASP65-GFP were selected.
 
Preparation of cell extracts
 
Floating cells were harvested by gentle aspiration of the cell medium and
pelleted by centrifugation. After washing with ice-cold PBS, cell pellets
were solubilized in boiling SDS sample buffer. Remaining adherent cells
were washed with ice-cold PBS and pooled with the extract prepared from
floating cells from the same dish to form a total cell population extract.
DNA was sheared by vortexing in the presence of glass beads, and the ex-
tracts were cleared by centrifugation at 15,000 
 
g
 
 for 10 min. Samples were
analyzed by SDS-PAGE and immunoblotting with appropriate antibodies.
 
In vitro cleavage experiments
 
Cytosol was prepared from suspension HeLa cells and desalted into buffer
A according to Lowe et al. (2000). MCF-7 cytosol was made in acetate/su-
crose buffer containing 2 mM ATP according to Lane et al. (2001). Cyto-
sols were supplemented with an ATP regeneration cocktail (10 mM cre-
atine phosphate, 40 
 
 
 
g/ml creatine kinase). To make cytosol apoptotic, 10
 
 
 
M cytochrome c was added. Where indicated, 2 
 
 
 
M Ac-DEVD-CHO
(Calbiochem) was added. Typically, 50 
 
 
 
g rat liver Golgi membranes (Hui
et al., 1998) were incubated with 200 
 
 
 
l HeLa cytosol (9 mg/ml) for vari-
ous times at 37
 
 
 
C, chilled on ice, and centrifuged at 100,000 
 
g
 
 for 15 min
to pellet the membranes. Pellet and supernatant fractions were solubilized
in SDS sample buffer and subjected to SDS-PAGE and Coomassie blue
staining or immunoblotting. For the Casputin™ experiment, cytosol was
 
preincubated for 90 min at 37
 
 
 
C with or without 10 
 
 
 
M cytochrome c be-
fore addition of the Golgi membranes. Incubations were then performed in
the absence or presence of 80 
 
 
 
g/ml Casputin™ (BioMol Research Labs).
In vitro synthesis of 
 
35
 
S-labeled recombinant proteins was performed us-
ing a coupled in vitro transcription/translation kit (Promega) according to
the manufacturer’s instructions. Typically, 9 
 
 
 
l of protein translate was
mixed with 45 
 
 
 
l of HeLa cytosol (9 mg/ml) and incubated for various
times at 37
 
 
 
C. Incubations with MCF-7 cytosol (4.5 mg/ml) were per-
formed for 2 h at 32
 
 
 
C. Alternatively, 1 
 
 
 
l of translate was added to 9 
 
 
 
l of
recombinant caspase 2, 3, or 7 (Alexis Biochemicals) and incubated for 2 h
at 30
 
 
 
C. Incubations with recombinant caspases were performed in 0.1%
CHAPS, 10% (wt/vol) sucrose, 5 mM DTT, 2 mM EDTA containing either
50 mM MES, pH 5.5 (caspase 2), or 50 mM Hepes, pH 7.4 (caspases 3 and
7). Samples were diluted into SDS sample buffer and analyzed by SDS-
PAGE and autoradiography.
 
Fluorescence microscopy
 
Conventional digital epifluorescence images of fixed cells were obtained
using an Olympus BX60 upright microscope equipped with a MicroMax-
cooled, slow scan CCD camera (Roper Scientific) driven by Metamorph
software (Universal Imaging Corp.). Confocal images were obtained using
a Leica NT confocal microscope. All images are projections of optical sec-
tions taken in the z-axis at 0.5-
 
 
 
m intervals.
For digital time-lapse analysis of live HeLa cells stably expressing wild-
type or caspase-resistant GRASP65-GFP, cells were grown on coverslips in
3-cm plastic cell culture dishes (Matek). Cells were treated with 5 
 
 
 
g/ml
anisomycin in CO
 
2
 
-independent, serum- and phenol red-free Leibovitz
L15 medium (GIBCO BRL) supplemented with 0.5% Alexa 594–conju-
gated annexin V (Molecular Probes) and 2.5 mM CaCl
 
2 
 
and were imaged
at 37
 
 
 
C by time-lapse fluorescence and phase–contrast microscopy using
an Olympus IX-70 inverted microscope equipped with a heated stage and
a PentaMax intensified cooled frame transfer CCD camera (Roper Scien-
tific). Images were obtained over a period of 3 h with 1-min time-lapse in-
tervals using halogen bulb illumination for both phase and fluorescence
with excitation and emission filter wheels and shutters (Sutter Instrument
Co.) controlled by Metamorph software.
To assess effects of GRASP65 expression on Golgi fragmentation, HeLa
cells stably expressing GRASP65-GFP (wild-type and caspase-resistant)
and the parental HeLa cell line were grown on coverslips for 24 h and then
treated with 2 
 
 
 
M staurosporine for 6 h. Cells were fixed in 
 
 
 
20
 
 
 
C metha-
nol for 5 min and then stained with antibodies to GM130 (Transduction
Labs) and caspase-cleaved PARP (Promega) followed by anti–mouse Alexa
488 and anti–rabbit Alexa 594 as described above. Cells were then ana-
lyzed blind for apoptotic stage and for Golgi morphology as described in
Fig. 7. Golgi-associated green fluorescence derived from GRASP65-GFP
plus
 
 
 
GM130/Alexa 488 in the stable cell lines was indistinguishable from
GM130/Alexa 488 staining alone in the parental HeLa cells.
Tests of association between cell type and fragmentation stage were
made between each pair of cell types using a chi square likelihood ratio
contingency test. To maintain a family wise type 1 error rate within each
fragmentation stage, we used the highly conservative correction of divid-
ing the family wise type I error rate by the number of test performed (0.05/3
in our case). Thus, each test within stage 1 and 2 had a type I error rate of
0.0167. Since experiments were combined for stage 3, no correction was
made for this group. All analyses were run in Systat version 10 (SPSS Inc.).
 
EM
 
Cells were fixed by adding 2% glutaraldehyde in 0.4 M Hepes buffer, pH
7.2, to an equal volume of the medium for 30 min, washed in PBS,
scraped with a rubber policeman, and pelleted. Cells were processed for
cryosectioning and immunogold labeled for GalNac T2 as described in
Farmaki et al. (1999) except the sections were picked up using the modi-
fied pick up method of Liou et al. (1996) using one part methyl cellulose
and three parts 2.3 M sucrose in PBS. For structural and quantitative analy-
sis, cells were post fixed with reduced osmium tetroxide, embedded in ep-
oxy resin, and after ultrathin sectioning contrast, lead citrate according to
Lucocq et al. (1989). For quantitation of gold labeling, cell profiles con-
tained in a randomly selected grid square were scanned systematically,
and Golgi areas were identified by the presence of cisternal stacks and/or
vesicular profiles labeled for GalNac T2. Labeling was assigned to one of
three categories: (1) Golgi stacks containing at least two juxtaposed elon-
gated profiles (with a length to width ratio of greater than four); (2) small
vesiculo-tubular profiles with a diameter of 
 
 
 
80 nm; (3) large electron-
lucent vesicles with a diameter of 
 
 
 
80 nm and pale staining content. In
epoxy resin sections, line intersections with the above classes of structure
were counted on micrographs taken at 15,000
 
 
 
 magnification or greater 
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and scanned on a flat bed scanner at a resolution of at least 1,000 pixels
per inch. The images were viewed and analyzed using intersection counts
on membrane-bound structure with lines of a square lattice grid (spacing
of 253 nm) in Adobe Photoshop
 
®
 
 5.5. Coefficients of error for ratio esti-
mates were calculated according to Cochran (1977).
 
Online supplemental material
 
Video 1 shows time-lapse analysis of anisomycin-treated HeLa cells stably
expressing wild-type GRASP65-GFP. Video 2 shows time-lapse analysis of
anisomycin-treated HeLa cells stably expressing caspase-resistant mutant
GRASP65-GFP. Fig. S1 shows the immunofluorescence pattern of stably
expressed wild-type and capase-resistant mutant GRASP65-GFP relative to
that of the endogenous Golgi proteins p115, GM130, GalNacT2, and
TGN46. Fig. S2 shows a Western blot of NRK and wild-type and mutant
GRASP65-GFP stable HeLa cells with antibodies to GM130, GRASP65,
and tubulin. Videos 1 and 2 and Figs. S1 and S2 are available online at
http://www.jcb.org/cgi/content/full/jcb.200110007/DC1.
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